Diagnostic

Labor and Delivery technology that improves risk prediction 10x for postpartum hemorrhage, saving lives, reducing maternal complications and cutting obstetrics costs for health systems and payers.

We create human-mimicking artificial tumors for high-throughput drug screening, enabling more accurate identification of promising drugs during the preclinical stage.

Moleculera Biosciences is a precision diagnostics company pioneering clinical diagnostics services for inflammatory brain and cardiovascular disorders using an integrated business model. The company enables clinicians to accurately diagnose, treat, and monitor patients suffering from chronic immune-mediated disorders, leading to remarkable recoveries.

Key highlights include:

• Autoimmune Brain Panel®: Generated $1.2MM in 2024 without a sales team
• Product pipeline: Preparing to launch the Autoimmune Cardiovascular Panel™ in 2026 and the Autoimmune Alzheimer's Panel™ in 2027
• Predictive treatment algorithm: Developing an algorithm leveraging a 16,000 clinically annotated biobank and bioinformatics repository to eliminate the trial-and-error of prescribing for these disorders
• Biorepository potential: Leveraging the repository to identify new companion diagnostics and novel targets for therapy

Parasight System Inc. has developed and manufactures a veterinary diagnostic analyzer that combines antigen-based fluorescence detection with advanced AI-powered image recognition technology, delivering highly accurate and efficient analysis for a variety of diagnostic tests and different medium, including fecal, heartworm, and Lyme disease tests in veterinary practices.